MedTrace Logo

Prospective Study of Ultrahypofractionated Proton Beam Therapy for Localized Prostate Cancer

NCT07699705 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-07-13

No results posted yet for this study

Summary

The goal of this prospective observational cohort study is to evaluate the long-term efficacy and safety of ultrahypofractionated proton beam therapy in patients with localized prostate cancer and to identify clinical and treatment-related factors associated with oncologic outcomes and treatment-related toxicity.

The main questions it aims to answer are:

What are the long-term biochemical recurrence-free survival, clinical progression-free survival, overall survival, and acute and late treatment-related toxicity outcomes following ultrahypofractionated proton beam therapy? Which clinical characteristics, treatment planning parameters, and patient-reported outcomes are predictive of long-term oncologic outcomes and treatment-related toxicity?

Participants will:

Receive protocol-based ultrahypofractionated proton beam therapy (35-40 Gy\[RBE\] in 5 fractions).

Undergo routine clinical evaluation, laboratory testing including prostate-specific antigen (PSA), and imaging studies according to the institutional follow-up schedule.

Complete patient-reported outcome questionnaires (EPIC-CP and Visual Analog Scale \[VAS\]) before treatment and during follow-up.

Be followed prospectively to assess biochemical recurrence, clinical progression, survival outcomes, and acute and late treatment-related toxicities.

Conditions

  • Prostate Neoplasm

Interventions

RADIATION

Ultrahypofractionated Proton Beam Therapy

Ultrahypofractionated proton beam therapy is delivered using pencil beam scanning (PBS) with image-guided proton therapy. Before treatment planning, all participants undergo placement of an absorbable rectal hydrogel spacer and two intraprostatic gold fiducial markers. Treatment planning is performed using CT simulation with MRI fusion after hydrogel stabilization. Daily cone-beam CT (CBCT) with fiducial marker matching is used for image guidance and patient positioning. A total dose of 36.25-40.0 Gy(RBE) is delivered in 5 fractions over approximately 1-2 weeks. Unlike conventional proton beam therapy using opposed right and left lateral beam arrangements, this protocol employs four oblique beam angles (right anterior oblique, right posterior oblique, left posterior oblique, and left anterior oblique) to optimize dose conformity while minimizing radiation exposure to adjacent normal tissues.

Sponsors & Collaborators

  • National Cancer Center, Korea

    lead OTHER_GOV

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-04
Primary Completion
2034-12-31
Completion
2034-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07699705 on ClinicalTrials.gov